PI4KA and cancer: Here we show that low doses of the PI4KA-specific inhibitor C7 are synergistic with the clinical KRASG12C-specific inhibitor sotorasib, resulting in near complete ablation of the transformed growth of KRASG12C-mutant human cancer cell lines.